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Tumor growthExcessive generation of reactive oxygen species (ROS) in cancer cells is associatedwith cancer development, but
the underlying mechanisms and therapeutic signiﬁcance remain elusive. In this study, we reported that levels of
ROS and p22phox expression are greatly increased in human prostate cancer tissues, and knockdownof p22phox by
speciﬁc small interfering RNA (siRNA) decreased ROS levels in prostate cancer cells. We also showed that stable
downregulation of p22phox in prostate cancer cells inhibited cell proliferation and colony formation, which was
mediated by AKT and extracellular signal-regulated kinase (ERK)1/2 signaling pathways and their downstream
molecules hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). The NADPH ox-
idase subunit NOX1 was also elevated in prostate cancer cells, and was involved in activation of AKT/ERK/HIF-1/
VEGF pathway and regulation of cell proliferation. Knockdown of p22phox resulted in inhibition of tumor angio-
genesis and tumor growth in nude mice. These ﬁndings reveal a new function of p22phox in tumor angiogenesis
and tumor growth, and suggest that p22phox is a potential novel target for prostate cancer treatment.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Prostate cancer is one of the leading causes of cancer death among
men in the world. The number of men diagnosed with prostate cancer
has been increasing over the past two decades [1]. Reactive oxygen spe-
cies (ROS) have been associated with prostate cancer development
through increasing cell proliferation and metabolism [2,3]. Elevated
levels of ROS are observed in breast cancer, ovarian cancer and colon
cancer [4,5]. Previous studies found that prostate cancer cells spontane-
ously produced much higher levels of ROS than immortalized epithelialpoxia-inducible factor 1α; VEGF,
um; CM-H2DCFDA, 5-(and-6)-
DHE, dihydroethidium; CCK-8,
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.Open access under CC BY-NC-ND licecells [6], and NOX1 induction increased ROS levels in the cells [17].
However, the sources of excessive ROS in prostate cancer cells and
the molecular mechanism of endogenous ROS in regulating tumor-
induced angiogenesis and tumor growth remain to be investigated.
There are many cellular systems generating ROS such as NADPH
oxidase, mitochondrial electron chain and xanthine oxidase [7–11].
The NADPH oxidase (NOX) consists of a membrane-bound complex
(subunit NOX isoform and p22phox) and four cytosolic subunits
(p47phox, p67phox, p40phox and the small GTPase RAC) [12,13]. The trans-
membrane subunit p22phox forms a mutually stabilizing complex with
NOX isoform (NOX1, NOX2, NOX3, NOX4, NOX5, Duox1 or Duox2),
followed by the recruitment of cytosolic subunits to form an active com-
plex. So far, this system is generally recognized as the predominant
source of ROS in endothelial cells [14].
Growing evidence reveals that NOX-dependent ROS production reg-
ulates several pivotal components of tumor growth, such as cancer cell
invasion, migration and proliferation [15–17]. NOX-derived ROS have
been associated with cell proliferation, malignant transformation and
cell survival through receptor tyrosine kinase (RTK) mediated mito-
genic pathways [18,19], signal transducer and activator of transcrip-
tion (STAT) pathway [20], and PI3K–AKT pathway [21]. A few studies
showed that p22phox is overexpressed in renal cell carcinoma [22],nse.
3376 Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385anaplastic thyroid carcinoma [23] and melanoma [16]. In human
melanoma, using targeted approaches against p22phox displayed re-
duced cell proliferation, supporting a role of p22phox in mitogenic
signaling.
Tumor angiogenesis is required for tumor growth and metastasis
since tumors cannot grow without nutrients and oxygen when theirCM-H2DCFDA H&EA
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3377Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385In this study, we aim to determine (i) the expression levels of ROS
and p22phox in prostate cancer tissues and cells; (ii) the downstream
signaling pathways upon p22phox activation; and (iii) the functional
role of p22phox activation in tumor angiogenesis and tumor growth.
2. Materials and methods
2.1. Cell culture and reagents
The human prostate cancer cells PC-3 and DU-145 (American Type
Culture Collection, Manassas, VA, USA) were cultured in RPMI 1640
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS) plus 100 units/ml penicillin and 100 μg/ml strepto-
mycin. Antibodies against HIF-1α and HIF-1βwere from BD Biosciences
(Franklin Lakes, NJ, USA). Antibodies against phospho-AKT, AKT,
phospho-ERK, ERK phospho-p70S6K1 and p70S6K1 were from Cell
Signaling (Beverly,MA, USA). The p22phox andVEGF antibodieswere pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The CD31
antibody was from Dako (Carpinteria, CA, USA). The antibody against
GAPDHwas from Sigma (St. Louis, MO, USA). The growth-factor reduced
phenol red-free Matrigel was from BD Biosciences (Bedford, MA, USA).
2.2. Human prostate tissue samples
Tissues were obtained from Huai'an First People's Hospital, Jiangsu,
China. 12 paired human prostate tumor and normal adjacent tissues
were obtained from patients during therapeutic surgery. Total 5
human normal prostate tissues and 33 human prostate cancer tissues
were obtained as parafﬁn-embedded, formalin-ﬁxed blocks. For all
cases, the pathological diagnosis and grading were conﬁrmed by two
experienced pathologists in accordance to the principles of World
Health Organization Classiﬁcation. The study was approved by the
Nanjing Medical University Ethics Committee with the informed con-
sent of all the patients.
2.3. ROS measurement
Human prostate tissues collected from fresh radical prostatectomies
were frozen in OTC and stored at−80 °C until use. Ten-micrometer fro-
zen sections of each sample were obtained at −20 °C using a cryostat
(Leica, Electronic). Frozen sections were thawed at room temperature
in the dark, and 200 μl of 10 μM CM-H2DCFDA (Invitrogen, USA) or
10 μMDHE (Sigma, USA) was added to immerse the tissues. After incu-
bation with CM-H2DCFDA or DHE for 15 min at 37 °C, the images of
tissues were captured by a ﬂuorescent microscope. The ROS signals
were quantiﬁed by ImageJ software.
PC-3 and DU-145 cells were seeded in a 6-well plate at
3 × 105 cells/well and cultured for 16 h, and then were transiently
transfected with p22phox siRNA or scramble siRNA. Then the cells were
cultured for 48 h, and incubated with 10 μM CM-H2DCFDA or 10 μM
DHE (Sigma, USA) in the dark for 15min at 37 °C. The cells were washed
twice with PBS, harvested and resuspended in the medium without CM-
H2DCFDA. ROS levelsweremeasured by a ﬂow cytometerwith excitation
at 488 nm and emission at 530 nm.
2.4. Immunoblotting
The cells were homogenized in a chilled lysis buffer containing
10 mM Tris–HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% SDS,
150 mM NaCl, 1 mM EDTA, and 1% protease inhibitors, sonicated, and
centrifuged for 15 min at 12,000 g at 4 °C. Lysate proteinswere separat-
ed by SDS-PAGE and electrophoretically transferred to a nitrocellulose
membrane (Whatman, Germany). Nonspeciﬁc binding was blocked
for 1 h with 5% non-fat dry milk for 1 h. Membranes were incubated
with primary antibody for 2 h and then for 1 h with peroxidase-conjugated secondary antibody. Protein blots were visualized with an
enhanced chemiluminescence reagent (Pierce).
2.5. Quantitative real-time PCR
Quantitative real-time RT-PCR was used to determine the expression
levels of p22phox and VEGF in cells. RNAs were extracted using a Trizol re-
agent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's
instruction. Reverse transcription of RNAswas performed using SYBR Pre-
mix DimerEraser (TaKaRa, Dalian, China) according to themanufacturer's
instruction. Real-time PCR was performed using A7500 Real-Time Ther-
mal Cycler (ABI). The following primer sequences were used for real-
time PCR: p22phox forward primer: 5′-ATTGTGGCGGGCGTGTT-3′; reverse
primer: 5′-CGGCGGTCATGTACTTCTGTC-3′; VEGF forward primer: 5′-
CGAGGGCCTGGAGTGTG-3′; reverse primer: 5′-CCGCATAATCTGCATGG
TGAT-3′; and GAPDH forward primer: 5′-ATGGGTGTGAACCAT
GAGAAGTATG-3′; reverse primer: 5′-GGTGCAGGAGGCATTGCT-3′. The
expression levels of p22phox and VEGF were normalized to the
value of GAPDH, and fold changes were calculated by relative quan-
tiﬁcation (2−ΔΔCt).
2.6. Transient transfection
Small interfering RNA (siRNA) duplex oligonucleotides targeting
human p22phox or scramble were purchased from GenePharma
(Shanghai, China). PC-3 and DU-145 cells were cultured to 60% to 70%
conﬂuence in 35-mm dishes, and were transfected with p22phox
siRNA or scramble siRNA using Lipofectamine RNAiMax (Invitrogen,
CA, USA) in serum free OPTI-MEM according to the manufacturer's
instruction.
The sequences of small interfering RNAs for p22phox are:
1# 5′-UAGUAAUUCCUGGUAAAGG-3′
2# 5′-AAAGUACCACUGGGUGAAG-3′.2.7. Luciferase assay
PC-3 and DU-145 cells were seeded into 24-well plates and cultured
overnight. Human VEGF reporter constructwas co-transfected into cells
with Renilla luciferase plasmids pGL4.74 and p22phox siRNA or scramble
control siRNA (siSC). The cells were cultured for 48 h after the transfec-
tion. Luciferase activity wasmeasured using the Dualluciferase Reporter
Assay System (Promega), and normalized to the corresponding controls
as described previously [26].
2.8. Establishment of stable prostate cancer cell lines
pLe-shp22phox plasmid was from a lentivirus-based human shRNA
library (GeneChem, Shanghai, China). In short, pLe-shp22phox plasmid
DNA and the transfection complex DNAs were transfected into 293T
cells using Trans-lentiviral package kit (Open Biosystems) to generate
lentivirus soup. The validated, non-silencing, scrambled control plasmid
pLe-shSCR was also transfected into 293T cells as a vector control.
Lentiviruses in the supernatant were collected and used to transduce
PC-3 and DU-145 cells followed by puromycin selection.
2.9. Cell proliferation assay
PC-3 and DU-145 cells stably expressing pLe-shSCR and pLe-
shp22phox were trypsinized and resuspended. Cells were seeded at
3000 cells per well in a 96-well plate. The cell proliferation was
measured at 12 h, 24 h, 48 h, 72 h and 96 h using Cell Counting Kit-8
(CCK-8) (Dojindo Laboratories, Kumamoto, Japan) according to the
manufacturer's instruction. All experiments were performed in tripli-
cate and were repeated for three times.
Table 1
Immunohistochemical analysis of p22phox expression levels in prostate cancer specimens.
Staining with
p22phox antibody
WHO grade Metastasis
I–II (n = 10) III–IV (n = 23) No (n= 11) Yes (n= 22)
0 and 1 8 (80%) 7 (30%) 2 (18.2%) 7 (31.8%)
2 and 3 2 (20%) 16 (70%) 9 (81.8%) 15 (68.2%)
P 0.02 0.68
3378 Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–33852.10. Soft agar assay
A total of 4000 cells was suspended in 0.3% low melting agarose
(Sigma) dissolved in 2 ml of RPMI 1640 with 10% FBS, and plated on
top of 2 ml 0.6% agarose in 6-well plates. After 2 weeks of incubation,
the colonies were ﬁxed in methanol and stained with 0.1% crystal
violet (Sigma). The colonies with a diameter of more than 1.5 mm
were counted. The experiments were performed in triplicates, and
were repeated three times.
2.11. In vivo angiogenesis and tumor growth assay
The 6-week-old male nude mice [BALB/cA-nu (nu/nu)] were
purchased from the Shanghai Experimental Animal Center (Chinese
Academy of Sciences, China), maintained in pathogen-free conditions,
and sustained with standard diets. All studies were approved by the
Institutional Committee on Animal Care of Nanjing Medical University.
For angiogenesis experiments in nude male mice, animals were ran-
domly divided into two groups (n= 4). PC-3 cells were transiently
transfectedwith p22phox siRNAand scramble control siRNA, respectively.
After being cultured for 48 h, aliquots of cells (2.0 × 106 cells) mixed
with 0.2 ml growth factor-reduced Matrigel were injected subcutane-
ously into both ﬂanks of nude mice. After 12 days of injections, the
Matrigel plugswere removed and photographed. Parts of the tissue sam-
ples were immersed immediately in lysis buffer (1 mM EDTA and 5 mM
phosphate, pH 8), and were incubated at 4 °C for 24 h. Hemoglobin con-
tents were measured using a Drabkin's Reagent Kit (Sigma-Aldrich, St.A
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Fig. 2. p22phox is required for ROS generation in prostate cancer cells. (A and B) ThemRNA level
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For tumor growth assay, animalswere randomly divided into twogroups
(n= 8). PC-3 cells stably expressing shp22phox or scramble shRNAwere
implanted subcutaneously at 6 × 106 cells into ﬂanks of male nudemice.
Tumor volumes were measured twice a week and calculated as follows:
(tumor width)2 × (tumor length) × 0.5. After 5 weeks of injections, the
mice were photographed, sacriﬁced, and the xenograft tumors were re-
moved from the mice and analyzed.2.12. Immunohistochemical staining
Tissue sectionswere incubatedwith p22phox, VEGF and humanCD31
primary antibodies in a humid chamber at 4 °C overnight for immuno-
histochemical staining. After washing in PBS buffer, sections were
incubated with secondary antibodies for 1 h at room temperature, and
then the immunoreactivity was detected by incubating in DAB (Gene
Tech, Shanghai, China). The assessment of immunohistochemistry was
performed by two experienced pathologists in a blind manner. For
each sample, ﬁve high-power ﬁelds (200×) were randomly selected.
The percentages of positive tumor cells and staining intensity were
assessed. The intensity of staining was categorized into ﬁve semi-
quantitative classes based on the percentages of positive tumor cells:
0 (≤5% positive cells), 1 (6%–25% positive cells), 2 (26%–50% positive
cells), 3 (51%–75% positive cells) and 4 (N76% positive cells). The levels
of staining intensity were also determined semi-quantitatively on a
scale of 0–3 as follows: 0 (negative), 1 (weakly positive), 2 (moderately
positive) and 3 (strongly positive). Multiplication of the intensity and
the percentage scores gave rise to the ﬁnal staining scores: 0 (negative),
+ (1–4), ++ (5–8), and +++ (9–12) [27,28].
The relative angiogenesis levels were estimated by micro-vessel
density (MVD) as described previously [29–31]. Brieﬂy, slides were
ﬁrst scanned under low magniﬁcation (×40) in order to determine
three ‘hot-spots’ or areas with the maximum number of microvessels,
which were then evaluated at ×200 magniﬁcation. The number of
microvessels in each ﬁeld was counted and their average numbers
were expressed as MVD per ﬁeld.siSCR
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All the results were obtained from at least three independent exper-
iments. The data are presented as mean± SD. The differences of the
results among the groups or treatments were statistically analyzed
using Student's t test and χ2 test. All results were performed using
GraphPad Prism 5.01. Differences were considered signiﬁcant at a
value of P b 0.05.GAPDH
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3.1. Human prostate tumors showed increased levels of ROS and expression
of p22phox
To compare ROS levels between prostate cancer tissues and normal
tissues, we utilized 12 paired fresh human prostate tissues to analyze
ROS levels by the CM-H2DCFDA staining method. As shown in Fig. 1A,DU-145
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3380 Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385the intensities of ﬂuorescence in cancerous regionswere approximately
2.8-fold higher compared with their corresponding adjacent normal
prostate epithelium tissues. Next, we stained the tissues with another
ﬂuorescent dye DHE to determine the superoxide levels. Similarly,
DHE-staining signals were 2.4-fold higher in the prostate cancer tis-
sues compared with the adjacent normal prostate epithelium tissues
(Fig. 1B).
The NADPH oxidase is recognized as an important source of ROS in
endothelial cells [14]. The p22phox is an indispensable subunit of
NADPH oxidase [12]. In this study, we analyzed p22phox protein levels
in 5 normal prostate cancer tissues and 33prostate cancer tissues by im-
munohistochemistry. As shown in Fig. 1C, there wasmodest expression
of p22phox in the normal epithelium, whereas a robust immunoreactiv-
ity was seen in the malignant epithelium tissues. A positive correlation
between p22phox expression levels and tumor grades was observed
(Table 1, P = 0.02). Although 68.2% of the patients with metastatic
lesions had a stronger p22phox expression, no correlation was found
between p22phox expression and tumor metastasis in prostate cancer
patients (Table 1, P = 0.68). Further experiments were performed by
using PC-3 and DU-145 prostate cell lines to assess the expression
levels of various catalytic subunits of NADPH oxidase. P22phox mRNA
levels were highly expressed in both cell lines, whereas the expression
levels of other NOX family members NOX1, NOX2 and NOX4 were
also increased (Fig. 1D).
3.2. Endogenous p22phox was upregulated in prostate cancer cells, which
correlates with increased ROS levels
Our previous study showed spontaneously high production of
ROS in PC-3 and DU-145 cells [6]. To determine the role of p22phox in
ROS production, we designed three small interfering RNA speciﬁcally
against p22phox (siRNA). Among the three sequences tested, transient
transfection with sip22phox#1or sip22phox#2 in PC-3 and DU-145 cells
effectively blocked endogenous p22phox mRNA and protein levels up
to 60–90% (Fig. 2A and B). Then, we examined the ROS levels in PC-3-
siSCR and PC-3-sip22phox cells. Intracellular CM-H2DCFDA and DHE
staining methods to detect ROS levels in PC-3 and DU-145 cells were
validated by the addition of NADPH oxidase inhibitor DPI or ROS
scavenger catalase (Fig. S1A–E). Knockdownof p22phoxwith two siRNAs
decreased ROS levels using intracellular CM-H2DCFDA staining by
ﬂow cytometry (Fig. 2C), indicating that p22phox is required for ROS
generation. As sip22phox#2 was more efﬁcient in suppressing ROS
levels, we used this siRNA sequence in subsequent experiments.3.3. p22phox enhanced cell growth in vitro
To examine the possible function of p22phox on cell growth, human
prostate cancer cell lines PC-3 and DU-145were infected with the lenti-
virus carrying p22phox short hairpin RNA (pLe-shp22phox) or the scram-
bled control (pLe-shSCR) followed by puromycin selection. As shown in
Fig. 3A and B, the expression levels of p22phox were similar inmock cells
and pLe-shSCR cells, but were decreased by 7- and 5-fold in pLe-
shp22phox-expressing PC-3 and DU-145 cells, respectively. Other
NADPH oxidase subunits were not affected by stable transfection with
pLe-shp22phox (Fig. S2A and S2B).
Cell proliferation and anchorage-independent colony assay were
performed in pLe-shp22phox stable cells. As illustrated in Fig. 3C,
p22phox knockdown cells attenuated cell proliferation starting at 72 h
after the seeding of both PC-3 and DU-145. Soft agar assay was per-
formed to evaluate the tumorigenic potential in p22phox knockdown
cells. Compared with the scrambled control (pLe-shSCR), knockdown
of p22phox resulted in reduced colony formation ability of more than
40% in both cell lines (Fig. 3D and E). Taken together, these results dem-
onstrate that endogenous p22phox promotes cell growth in vitro.
It was reported that NOX1 expression and H2O2 levels were upregu-
lated in prostate cancer, and overexpression of NOX1 promoted
tumor angiogenesis and tumor growth [17,36]. Similar results were ob-
tained that knockdown of NOX1 decreased cell proliferation when we
transfected PC-3 cells and DU-145 cells using NOX1 siRNA, shNOX1
(Fig. 3F and G).
3.4. p22phox regulated HIF-1 and VEGF expression via AKT and ERK1/2
signaling pathways
The phosphatidylinositol-3 kinase (PI3K)/AKT and mitogen activat-
ed protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)
cascades are frequently overactivated in cancer cells that play critical
roles in controlling cell metabolism, proliferation, and survival [32,33].
Our previous study showed that endogenous ROS can activate down-
stream PI3K/AKT and ERK1/2 pathways [34]. Indeed, knockdown
p22phox or NOX1 inhibited AKT and ERK1/2 activation (Fig. 4A and B).
We further examined mTOR and p70S6K1 that are known downstream
targets of AKT and ERK1/2. Decreased phosphorylation levels of mTOR
and p70S6K1 were observed in PC-3-pLe-shp22phox and DU-145-pLe-
shp22phox cells (Fig. 4A).
Hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial
growth factor (VEGF) are regulated by PI3K/AKT and MAPK/ERK
3381Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385signaling pathways [35]. Here we observed that knockdown of p22phox
decreased HIF-1α expression, whereas the HIF-1β level was not
changed (Fig. 4C and D). Similar effects were observed when PC-3
cells and DU-145 cells were transfected with shNOX1 (Fig. 4B). As
shown in Fig. 4E–F, VEGFmRNA expression levels in the cells expressing
siRNAs against p22phox or NOX1 were signiﬁcantly reduced compared
with control cells. To further analyze the mechanism of p22phox in reg-
ulating VEGF expression, PC-3 and DU-145 cells were co-transfected
with VEGF luciferase reporter and p22phox siRNA or scramble siRNA.
As shown in Fig. 4G, VEGF reporter activity was greatly inhibited by
sip22phox. These results suggest that p22phox regulates HIF-1 and VEGF
expression.GAPDH
p70
p-p70
p-mTOR
mTOR
P-AKT
AKT
p-ERK
ERK
A PC-3 DU-145
D
Mo
ck
pL
e-s
hS
CR
pL
e-s
hp
22
ph
ox
0.0
0.5
1.0
1.5 p=0.0080
**
PC-3
H
IF
-1
α
 /H
IF
-1
β
R
el
at
iv
e 
De
ns
ity
C PC-3
HIF-1α
HIF-1β
Fig. 4. P22phox affects AKT and ERK1/2 signaling pathways and HIF-1α and VEGF expression. (A,
p70S6K1, HIF-1α andHIF-1βwere analyzed byWestern-blotting. (D)HIF-1α andHIF-1β signal
experiments. Asterisk indicates signiﬁcant difference when compared to the control (P b 0.05)
formed in triplicate. ⁎ and ⁎⁎ indicated signiﬁcant difference at P b 0.05 and P b 0.01. (G) PC-3
VEGF promoter reporter pMAP11 wt and luciferase reporter pGL4.74. The relative luciferase ac
three independent experiments. ⁎⁎Double asterisk indicates signiﬁcant difference at P b 0.01.3.5. Knockdown of p22phox inhibited angiogenesis in vivo
HIF-1α and VEGF are important angiogenic factors for controlling
vasculature and angiogenesis [37–39]. To determine whether knock-
down of p22phox inhibits tumor angiogenesis in vivo, we generated
xenograft tumors in nudemice. PC-3 cells greatly induced angiogenesis,
which was inhibited by sip22phox (Fig. 5A). The hemoglobin contents in
the plug were used to evaluate angiogenesis responses. Knockdown of
p22phox decreased hemoglobin level to 40–50% of the scramble group
(Fig. 5B). In addition, the number of CD31-positive microvessels
was signiﬁcantly lower in xenograft tumors generated from PC-3
cells expressing sip22phox (Fig. 5C). Quantitative analysis by usingGAPDH
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3382 Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385microvessel density (MVD) showed that sip22phox treatment decreased
MVD by 25–35% (Fig. 5D). These results demonstrate that p22phox pro-
motes tumor-induced angiogenesis.
3.6. Knockdown of p22phox inhibited tumor growth in vivo
Angiogenesis is required for tumor growth and metastasis. To test
whether knockdown of p22phox inhibits tumor growth, we generated
xenograft tumors by the injection of stable PC-3/shp22phox or PC-3/
shRNA control cells subcutaneously into nude mice for 35 days. As
shown in Fig. 6A, the average sizes of tumors from shp22phox-
expressing cells were much smaller than those from scramble shRNA
control group after 5 weeks of growth. Shp22phox decreased tumor
growth by 70% compared with scramble shRNA (Fig. 6B and C).
We also analyzed p22phox, p-AKT, p-ERK, HIF-1α expression levels in
tumor tissues from two groups. As expected, tumor tissues fromp22phox
knockdown PC-3 cells had much lower expression levels of p22phox. In
addition, the lower levels of p22phox expression in the tumors from
PC-3-pLe-shp22phox cells were highly correlated with the expression
levels of p-AKT, p-ERK and HIF-1α protein (Fig. 6D). Similarly, the ex-
pression levels of VEGF in the tumor sections were also lower in the
PC-3-pLe-shp22phox group than those in the PC-3-pLe-shSCR group by
immunohistochemistry (Fig. 6E). Collectively, these results demon-
strate that knockdown of p22phox inhibits tumor growth via AKT and
ERK1/2 signaling pathways.
4. Discussion
Elevated ROS generation has long been associated with cancer de-
velopment in solid tumors [4,6,40]. However, many questions remain
to be answered such as the major sources of excessive ROS generation
in speciﬁc cancer cells and tissues, the connection of endogenous ROS
to signaling molecules and their biological responses. The NADPHoxidase is recognized as the predominant source of ROS in endothelial
cells. For example, the p47phox subunit is required for ROS generation
in ovarian cancer cells [6], whereas the catalytic subunit NOX1 has
been implicated in Ras-induced VEGF upregulation [41].
This study revealed the functional role of the small membrane-
bound subunit p22phox in prostate cancer development, and showed
the clinical relevance by utilizing human prostate cancer tissues. Pros-
tate cancer tissues havemuch higher ROS levels and p22phox expression
levels in this study. More importantly, p22phox expression levels were
positively correlated with tumor grades. Knockdown of p22phox de-
creased prostate cancer cell proliferation, formation capacity, and
inhibited tumor angiogenesis and tumor growth in a mouse xenograft
model.
We further explored the downstream pathway of p22phox. VEGF is
a key proangiogenic activator which can be induced at transcrip-
tional level by HIF-1α [39]. Knockdown of p22phox dramatically
downregulates HIF-1α protein expression as well as VEGF mRNA
levels, which is an indicative of involvement of HIF-1/VEGF pathway in
p22phox-induced angiogenesis. Previous studies showedROS can activate
downstream PI3K/AKT and ERK1/2 pathways, which regulate HIF-1 and
VEGF [4,35,42,43]. We demonstrated that p22phox is able to activate
PI3K/AKT and ERK1/2 pathways. mTOR is a Ser/Thr protein kinase
that functions as an ATP and amino acid sensor to balance nutrient avail-
ability and cell growth [44,45]. P70S6 kinase (p70S6K1) is a downstream
effector of mTOR which regulates protein translation by directly phos-
phorylating ribosomal protein S6 [46]. Both of them are known as the
downstream effectors of PI3K/AKT and ERK1/2 pathways [47–49]. In
this study, knockdown of endogenous p22phox was sufﬁcient to inhibit
mTOR and p70S6K1 activation, suggesting that p22phox mediated HIF-
1/VEGF activation possibly by increasing activities of PI3K/AKT and
ERK1/2 and the downstream targets mTOR and p70S6K1.
The mechanism by which ROS activate AKT and ERK1/2 is currently
unknown. One possibility is that AKT activation is due to ROS-
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ylates PIP3, the upstream activator of AKT [50–52]. However, PTEN ex-
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3384 Q. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 3375–3385Complex formation between NOX proteins and p22phox is known to
be required for NADPH oxidase activation. NOX1-derived ROS are asso-
ciated with tumor growth and tumor angiogenesis in prostate cancer
[17,36]. Our results showed that NOX1 expression was also induced in
prostate cancer cells, and involved in activation of AKT/ERK/HIF/VEGF
pathway, and upregulation of cell growth, suggesting that overexpres-
sion of p22phox as well as NOX1 contributes to prostate cancer develop-
ment via ROS signaling.
In conclusion, our present study showed that the expression levels of
p22phox and endogenous ROS are upregulated in prostate carcinoma. El-
evated p22phox expression promoted prostate cancer cell proliferation,
tumor growth and tumor angiogenesis through AKT/ERK/HIF/VEGF sig-
naling pathways. These results implicate that the blockade of p22phox
binding to the NOX catalytic subunits may act as a potential new thera-
peutic strategy for prostate cancer treatment in the future.
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